Kiniksa Pharmaceuticals International, plc
KNSA
Rankning i aktier
#2877
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aktiekurs
$83.13
Senast synkroniserad: 2026-10-20
Marknadsvärde
$6.49B
Förändring (1 dag)
4.59%
Förändring (1 år)
113.97%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Kategori
Healthcare
P/S-tal för Kiniksa Pharmaceuticals International, plc (KNSA)
P/S-tal per October 2026 TTM: 7.32
Enligt Kiniksa Pharmaceuticals International, plc senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 7.32. I slutet av 2023 hade företaget ett P/S-tal på 4.55.
Historik för P/S-tal för Kiniksa Pharmaceuticals International, plc från 2016 till 2026
P/S-tal vid årets slut
| År | P/S-tal | Ändra |
|---|---|---|
| 2026 (TTM) | 7.32 | 119.03% |
| 2024 | 3.34 | -26.59% |
| 2023 | 4.55 | -3.68% |
| 2022 | 4.72 | -77.46% |
| 2021 | 20.94 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
P/S-tal för liknande företag eller konkurrenter
| Företag | P/S-tal | Skillnad i P/S-tal | Land |
|---|---|---|---|
| 10.31 | 40.94% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 15.12 | 106.72% |
US
|
